Latest Campaign Updates

Trial registration may reduce publication bias

A new study in JAMA Internal Medicine has found that clinical trials on treatments for cardiovascular diseases that were registered were less likely to report positive results than unregistered trials. Researchers looked at clinical trials that were published on PubMed in December 2012 and found 191 on cardiovascular diseases, 45% of which had been registered. […]

23rd March 2015|

Overcoming Publication Bias in Clinical Trials: JNRBM article collection

This is a guest post by Ella Flemyng and Daniel Shanahan of BioMed Central, which is a supporter of the AllTrials campaign.

Clinical trials are one of our most valuable types of research for identifying cause-and-effect in healthcare interventions. However, while ‘positive’ results—those that support carefully-constructed hypotheses—often get the most attention, non-confirmatory or so-called ‘negative’ results […]

17th March 2015|

The Missing Pieces: A PLOS Collection of Negative, Null and Inconclusive Findings

This is a guest post by Jennifer Horsley, PLOS Collections, Meghan Byrne, PLOS ONE and Sarah Wade, PLOS ONE. PLOS is a co-founding organisation of AllTrials.

The publication of negative results is vitally important for many reasons, not least that it helps prevent duplication of research effort and potentially expedites the process of finding positive results. […]

16th March 2015|

Only 13% of clinical trials report results on time

A new study in the New England Journal of Medicine (NEJM) found that, despite being required to do so by law, most clinical trials aren’t reported within a year of completion. Under the FDA Amendment Act 2007 (FDAAA), most clinical trials in the US on treatments approved by the FDA have to publicly report their […]

13th March 2015|

Clinical trial results remain hidden when drugs are abandoned

Results from clinical trials on drugs approved by the US Food and Drug Administration (FDA) are almost three times more likely to be made public than results from trials on drugs that are not brought to market, according to a new study in The BMJ.

Researchers from McGill University investigated a total of 177 clinical trials, 96 […]

10th March 2015|

AllTrials on Australian prime-time TV

Australia’s only prime-time science show, Catalyst, discussed Tamiflu and the need the access for results from all clinical trials. The show interviews Dr Fiona Godlee, editor-in-chief of The BMJ and co-founder of AllTrials, and Professor Chris Del Mar, Coordinating Editor for the Acute Respiratory Group of the Cochrane Collaboration.
Narrator: The BMJ and Cochrane Collaboration are […]

3rd March 2015|

German study finds publicly available clinical trial information is incomplete

Details about what was done and what was found in clinical trials looked at by the German Institute for Quality and Efficiency in Health Care (IQWiG) are incomplete or missing from publicly available trial information according to a new study published in The BMJ. The researchers at IQWiG, who wrote the study, conclude that “a substantial […]

2nd March 2015|

Researchers “lack time” to publish results, new review finds

A “lack of time” is the most common reason researchers gave for not publishing their results in an academic journal after presenting them at a conference, according to a new systematic review in the Journal of Clinical Epidemiology. The authors of the review searched for studies that investigated whether abstracts presented at biomedical conferences were […]

24th February 2015|

AllTrials response to EMA consultation on implementing the European Clinical Trials Regulation

In April 2014, following all of your letters, the European Parliament passed the Clinical Trials Regulation with strong transparency measures. Now the European Medicines Agency is seeking feedback on how to implement the new law. You can read the consultation document here.

Read the AllTrials response here and below. Feel free to use our response to help […]

13th February 2015|

EMA explains redactions to trial documents

In a reply to questions from the European Ombudsman, the European Medicines Agency (EMA) has published its reasons for agreeing to keep clinical trial information hidden. In 2013, the EMA received requests for documents from clinical trials on the medicine Humira. AbbVie, the manufacturer of Humira, sued the EMA to prevent those documents from being […]

10th February 2015|